PharmaCyte Biotech Inc. (PMCB): Price and Financial Metrics
GET POWR RATINGS... FREE!
PMCB Stock Price Chart Interactive Chart >
PMCB Price/Volume Stats
| Current price | $2.94 | 52-week high | $3.10 |
| Prev. close | $2.91 | 52-week low | $1.79 |
| Day low | $2.87 | Volume | 64,162 |
| Day high | $2.95 | Avg. volume | 70,194 |
| 50-day MA | $2.94 | Dividend yield | N/A |
| 200-day MA | $2.58 | Market Cap | 55.06M |
PharmaCyte Biotech Inc. (PMCB) Company Bio
PharmaCyte Biotech, Inc. (PharmaCyte) is a biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed.
Latest PMCB News From Around the Web
Below are the latest news stories about PHARMACYTE BIOTECH INC that investors may wish to consider to help them evaluate PMCB as an investment opportunity.
PharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder ValueTopics to Include Continued Analysis of FDA’s Clinical Hold on IND for Cell-in-a-Box®LAS VEGAS, Oct. 07, 2022 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), a biotechnology company focused on evaluating its signature live-cell encapsulation technology, Cell-in-a-Box for potential development of cellular therapies for cancer, diabetes and malignant ascites, announces today that its Board of Directors has empowered its Business Review Committee to evalu |
PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois CapitalLAS VEGAS, August 15, 2022--PharmaCyte and Iroquois have reached a settlement which includes appointing five new independent directors to PharmaCyte's reconstituted Board. |
PharmaCyte Biotech Rebukes Iroquois’ Commencement of Consent SolicitationLAS VEGAS, July 28, 2022--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, today issued the following statement in response to Iroquois Capital’s filing of a preliminary consent statement to commence a consent solicitation in lieu of a stockholder meeting. Iroquois Capital is seeking the consent of the Company’s shareholders |
Iroquois Files Preliminary Consent Materials to Reconstitute Board of Directors at PharmaCyte Biotech, Inc.Iroquois Capital Management, LLC (together with its affiliates, "Iroquois"), one of the largest stockholders of PharmaCyte Biotech, Inc. ("PharmaCyte", "PMCB" or the "Company") (NASDAQ:PMCB), with an aggregate ownership stake together with the other participants in its solicitation of approximately 7.2% of the Company's outstanding shares, today announced that it has filed preliminary consent materials with the SEC regarding its solicitation of written consents from stockholders in lieu of a sto |
PharmaCyte Biotech Commences First Phase of Two-Phase Pig StudyLAS VEGAS, July 21, 2022--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has commenced the pilot phase of its two-phase pig study. The pig study is the last of several requirements PharmaCyte has complied with related to the requests from the U.S. Food and Drug Administration (FDA) to lift the clinic |
PMCB Price Returns
| 1-mo | 2.44% |
| 3-mo | -1.01% |
| 6-mo | 23.01% |
| 1-year | 44.12% |
| 3-year | -96.46% |
| 5-year | -97.32% |
| YTD | 0.34% |
| 2022 | 17.20% |
| 2021 | -75.12% |
| 2020 | -83.46% |
| 2019 | 9.46% |
| 2018 | -33.69% |
Loading social stream, please wait...